HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates.

AbstractPURPOSE:
To evaluate safety, feasibility and overall survival rates for transarterial chemoembolization (TACE) alone or combined with MR-guided laser-induced-thermotherapy (LITT) in liver metastases of non-colorectal and non-breast cancer origin.
METHODS AND MATERIALS:
Included were patients with unresectable non-colorectal non-breast cancer liver metastases with progression under systemic chemotherapy. Excluded were patients with Karnofsky score ≤ 70, respiratory, renal and cardiovascular failure, and general TACE contraindications. TACE using Mitomycin alone, Mitomycin-Gemcitabine or Mitomycin-Gemcitabine-Cisplatin was performed to all patients. After TACE 146 metastases were ablated with MR-guided LITT. To be eligible for LITT metastases should be < 5 cm in size and ≤ 5 in number. Tumor response was evaluated using MRI according to RECIST. Survival was evaluated using Kaplan-Meier analysis.
RESULTS:
A total of 110 patients (mean age 59.2 years) with 371 metastases received TACE (mean 5.4 sessions/patient, n=110) with 76 (69%) receiving LITT (mean 1.6 session/patient) afterwards. TACE resulted in a mean decrease of mean maximum diameter of 52% ± 26.6 and volume change of -68.5% ± 22.9 in the 25 patients (23%) with partial response. Stable disease (n=59, 54%). Progressive disease (n=26, 23%). The RECIST outcome after LITT showed complete response (n=13, 17%), partial response (n=1, 1%), stable situation (n=41, 54%) and progressive disease (n=21, 28%). The mean time to progression (TTP) was 8.6 months. Median survival of all patients was 21.1 months.
CONCLUSION:
TACE with different protocols alone and in combination with LITT is a feasible palliative treatment option resulting in a median survival of 21.1 months for unresectable liver metastases of non-colorectal and non-breast cancer origin.
AuthorsThomas J Vogl, Martin Kreutzträger, Tatjana Gruber-Rouh, Katrin Eichler, Nour-Eldin A Nour-Eldin, Stephan Zangos, Nagy N N Naguib
JournalEuropean journal of radiology (Eur J Radiol) Vol. 83 Issue 10 Pg. 1804-10 (Oct 2014) ISSN: 1872-7727 [Electronic] Ireland
PMID25082479 (Publication Type: Journal Article)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Contrast Media
  • Gadolinium DTPA
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage)
  • Chemoembolization, Therapeutic (methods)
  • Combined Modality Therapy
  • Contrast Media
  • Disease Progression
  • Female
  • Gadolinium DTPA
  • Humans
  • Hyperthermia, Induced (methods)
  • Laser Therapy (methods)
  • Liver Neoplasms (secondary, therapy)
  • Magnetic Resonance Imaging, Interventional
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Palliative Care
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: